Show simple item record

dc.contributor.authorSipilanyambe, Naawaen_US
dc.contributor.authorSimon, Jonathon Len_US
dc.contributor.authorChanda, Pascalinaen_US
dc.contributor.authorOlumese, Peteren_US
dc.contributor.authorSnow, Robert Wen_US
dc.contributor.authorHamer, Davidson Hen_US
dc.date.accessioned2012-01-09T20:58:40Z
dc.date.available2012-01-09T20:58:40Z
dc.date.copyright2008en_US
dc.date.issued2008-1-29en_US
dc.identifier.citationSipilanyambe, Naawa, Jonathon L Simon, Pascalina Chanda, Peter Olumese, Robert W Snow, Davidson H Hamer. "From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia" Malaria Journal 7:25. (2008)en_US
dc.identifier.issn1475-2875en_US
dc.identifier.urihttp://hdl.handle.net/2144/2947
dc.description.abstractBACKGROUND Following the recognition that morbidity and mortality due to malaria had dramatically increased in the last three decades, in 2002 the government of Zambia reviewed its efforts to prevent and treat malaria. Convincing evidence of the failing efficacy of chloroquine resulted in the initiation of a process that eventually led to the development and implementation of a new national drug policy based on artemisinin-based combination therapy (ACT). METHODS All published and unpublished documented evidence dealing with the antimalarial drug policy change was reviewed. These data were supplemented by the authors' observations of the policy change process. The information has been structured to capture the timing of events, the challenges encountered, and the resolutions reached in order to achieve implementation of the new treatment policy. RESULTS A decision was made to change national drug policy to artemether-lumefantrine (AL) in the first quarter of 2002, with a formal announcement made in October 2002. During this period, efforts were undertaken to identify funding for the procurement of AL and to develop new malaria treatment guidelines, training materials, and plans for implementation of the policy. In order to avoid a delay in implementation, the policy change decision required a formal adoption within existing legislation. Starting with donated drug, a phased deployment of AL began in January 2003 with initial use in seven districts followed by scaling up to 28 districts in the second half of 2003 and then to all 72 districts countrywide in early 2004. CONCLUSION Drug policy changes are not without difficulties and demand a sustained international financing strategy for them to succeed. The Zambian experience demonstrates the need for a harmonized national consensus among many stakeholders and a political commitment to ensure that new policies are translated into practice quickly. To guarantee effective policies requires more effort and recognition that this becomes a health system and not a drug issue. This case study attempts to document the successful experience of change to ACT in Zambia and provides a realistic overview of some of the painful experiences and important lessons learnt.en_US
dc.description.sponsorshipZambian-Boston University Malaria Project; Novartis Pharma AG; The Wellcome Trust UK; The Zambian Governmenten_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2008 Sipilanyambe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleFrom Chloroquine to Artemether-Lumefantrine: The Process of Drug Policy Change in Zambiaen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1475-2875-7-25en_US
dc.identifier.pubmedid18230140en_US
dc.identifier.pmcid2248595en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2008 Sipilanyambe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2008 Sipilanyambe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.